Zydus begins human trials for potential COVID-19 vaccine

In the human trials, Zydus will enrol over 1,000 subjects across multiple clinical study sites in India.

File photo for representational purpose only.

Pharmaceutical company Zydus said on Wednesday it has started human studies for its potential COVID-19 vaccine, as coronavirus infections continue to surge in the world's third worst-hit nation.

ZyCoV-D, its plasmid DNA vaccine, was found to be safe, immunogenic and well-tolerated in the pre-clinical toxicity studies, Zydus said.

In the human trials, Zydus will enroll over 1,000 subjects across multiple clinical study sites in India.